Gapping up
In reaction to earnings/guidance:
- ESTC +11.9%, CONN +6.2%, SMTC +4.9%, SMAR +4.7%, CIEN +2.3%, PAGS +2.2%, LESL +2.1%, EPRT +1.4%, DOOO +1%, GWRE +0.9%, PVH +0.6% (also CFO/COO leaving as is the CEO of its Calvin Klein unit), .
Other news:
- EBF +6.9% (acquires AmeriPrint)
- REAL +6.8% (provides business update; GMV QTD up 106% yr/yr)
- PTGX +6.6% (FDA grants Breakthrough Therapy Designation to rusfertide for treatment of patients with polycythemia vera)
- REPL +4.8% (provides data update from its RP1 (vusolimogene oderparepvec) and RP2 programs and announces plans to expand the development of RP2/3 beyond phase 1)
- VBLT +4.2% (announces a primary endpoint amendment in the OVAL Phase 3 registration-enabling study of VB-111)
- WVE +3.9% (reports proof-of-concept preclinical data for ADAR editing program)
- ALPN +3.6% (announces highlights from ALPN-303 data presentation)
- IGMS +2.6% (expects to advance first intranasally administered IgM Antibody, IGM-6268, into the Clinic in Q3)
- VAL +1.4% (awarded a two-well contract extension with Equinor Energy)
- TW +1.2% (reported total trading volume for May 2021 of $19.6 trillion)
Analyst comments:
- TLRY +4.5% (upgraded to Overweight from Neutral at Cantor Fitzgerald)
- CRTO +1.7% (upgraded to Buy from Hold at Stifel)
- TTWO +1.1% (upgraded to Buy from Hold at Jefferies)